// Metadata is defined in a separate module to satisfy ESLint rules.

export default function AiBiotechGenetics() {
  return (
    <div>
      <h2>I. Introduction: A Double Helix Meets an Algorithm</h2>
      <p>
        The convergence of Artificial Intelligence (AI) with the life
        sciences—specifically biotechnology, genetics, and bioinformatics—has
        catalyzed a paradigm shift in how we decode, manipulate, and engineer
        biological systems. What once took years to analyze by hand—such as
        sequence alignments, protein folding predictions, or gene-disease
        correlations—can now be processed in minutes by powerful AI models. But
        this revolution didn’t happen overnight. Its roots trace back to modest
        rule-based systems and neural nets in the early 2000s, evolving into
        today’s generative and predictive powerhouses.
      </p>
      <h2>II. From Statistical Genomics to Early ML (2000s – 2012)</h2>
      <h3>Early AI in Life Sciences: Weak Learners, Strong Potential</h3>
      <p>
        The early 2000s saw the rise of machine learning in bioinformatics,
        driven by the explosion of biological data from projects like the Human
        Genome Project (completed in 2003). At this stage, AI largely meant
        algorithms like support vector machines (SVMs), decision trees, random
        forests, and simple neural networks applied to:
      </p>
      <ul>
        <li>Gene expression profiling (microarray data)</li>
        <li>Protein sequence classification</li>
        <li>SNP (Single Nucleotide Polymorphism) association mapping</li>
        <li>Basic protein structure prediction</li>
      </ul>
      <p>Key applications included:</p>
      <ul>
        <li>
          BLAST and its successors incorporating machine learning for faster,
          more accurate sequence similarity search
        </li>
        <li>
          GENSCAN and GeneMark using probabilistic models to identify exons and
          introns in DNA sequences
        </li>
      </ul>
      <p>
        These approaches, while technically impressive, were limited in
        adaptability and scalability. They required structured input and
        meticulous feature engineering.
      </p>
      <h2>
        III. Deep Learning in Genomics (2012 – 2019): The Neural Network
        Renaissance
      </h2>
      <h3>The Shift: From Hand-Crafted Features to Representation Learning</h3>
      <p>
        With the ImageNet breakthrough in 2012, convolutional neural networks
        (CNNs) and recurrent neural networks (RNNs) were adapted to biological
        sequences. Genomics saw a massive leap in power and flexibility.
      </p>
      <h4>Notable Tools & Projects:</h4>
      <ul>
        <li>
          <strong>DeepBind (2015):</strong> Predicts DNA- and RNA-binding sites
          using CNNs
        </li>
        <li>
          <strong>DeepSEA (2016):</strong> Predicts the chromatin effects of
          noncoding variants
        </li>
        <li>
          <strong>Basenji / BPNet:</strong> Captures long-range regulatory
          activity in the genome
        </li>
        <li>
          <strong>AlphaFold (early versions):</strong> Deep learning applied to
          3D protein folding
        </li>
      </ul>
      <p>
        These models finally bypassed the need for manual alignment or motif
        identification by learning directly from raw sequence data.
      </p>
      <h4>Impacts on Genetic Discovery:</h4>
      <ul>
        <li>Improved interpretation of noncoding variants</li>
        <li>Optimized CRISPR guide design using neural networks</li>
        <li>
          Drug-target prediction models outperforming traditional QSAR methods
        </li>
      </ul>
      <h2>
        IV. 2020–Present: The Age of Foundation Models and Generative Biology
      </h2>
      <h3>LLMs & Transformers Enter the Lab</h3>
      <p>
        The explosion of large language models (LLMs) and transformer
        architectures has radically transformed bioinformatics. Tools like
        ProtBert, ESM (Meta), ProGen, and Geneformer applied transformers
        directly to protein sequences, gene regulatory data, and more.
      </p>
      <h4>Major Applications:</h4>
      <ul>
        <li>
          <strong>AlphaFold2 (2021):</strong> Revolutionized protein folding
          with attention-based mechanisms
        </li>
        <li>
          <strong>ESM-2 (2022–):</strong> Enables mutation impact prediction, de
          novo protein design, and structure recovery
        </li>
        <li>
          <strong>ProGen:</strong> Language model trained on protein families to
          create novel enzymes from scratch
        </li>
        <li>
          <strong>Geneformer (2023):</strong> Transformer model trained on gene
          expression atlases for gene interactions and cellular reprogramming
        </li>
      </ul>
      <h2>V. Real-World Use Cases and Milestones</h2>
      <h3>1. Drug Discovery and Protein Engineering</h3>
      <ul>
        <li>
          Insilico Medicine using LLMs and GANs to design small molecules
          rapidly
        </li>
        <li>
          DeepMind and Isomorphic Labs exploring disease pathways
          computationally
        </li>
        <li>
          Biotech companies like AbCellera, Genentech, and Recursion integrating
          AI across the pipeline
        </li>
      </ul>
      <h3>2. CRISPR Optimization</h3>
      <ul>
        <li>Predicting off-target effects with DeepCRISPR</li>
        <li>Designing gRNA libraries using reinforcement learning</li>
      </ul>
      <h3>3. Multi-omics Integration</h3>
      <ul>
        <li>
          Combining transcriptomics, epigenomics, and proteomics with
          variational autoencoders and graph neural networks (GNNs)
        </li>
      </ul>
      <h3>4. Synthetic Biology</h3>
      <ul>
        <li>
          Generative models designing new sequences with targeted functionality
        </li>
        <li>
          LLMs assisting in lab protocols, cloning strategies, and coding
          alternatives
        </li>
      </ul>
      <h2>VI. Challenges and Ethical Considerations</h2>
      <ul>
        <li>Data bias in training sets</li>
        <li>Limited interpretability of deep models</li>
        <li>Unclear regulatory pathways for AI-generated drug candidates</li>
        <li>
          Intellectual property challenges around AI-designed biomolecules
        </li>
      </ul>
      <h2>VII. Where to Next? The Frontiers of Bio-AI</h2>
      <ul>
        <li>
          Multimodal AI models combining text, sequences, microscopy, and
          structural data
        </li>
        <li>LLMs supporting bench work and lab automation</li>
        <li>Self-improving bio agents using real-time feedback</li>
        <li>
          Domain-specific models like BioGPT, BioMedLM, and SciPhi fine-tuned on
          scientific corpora
        </li>
      </ul>
      <h2>VIII. Conclusion</h2>
      <p>
        AI has not just augmented biotechnology and genetics—it is beginning to
        define their frontiers. What was once a discipline of slow,
        hypothesis-driven inquiry is now entering an era of predictive design,
        simulation-before-synthesis, and high-resolution biological insight. The
        question is no longer whether AI will revolutionize biology, but how we
        will shape that revolution to benefit science, medicine, and society.
      </p>
      <h2>References</h2>
      <ol>
        <li>
          Alipanahi, B. et al. (2015). Predicting the sequence specificities of
          DNA- and RNA-binding proteins by deep learning.{" "}
          <em>Nature Biotechnology.</em>
        </li>
        <li>
          Jumper, J. et al. (2021). Highly accurate protein structure prediction
          with AlphaFold. <em>Nature.</em>
        </li>
        <li>
          Madani, A. et al. (2020). ProGen: Language Modeling for Protein
          Generation. <em>bioRxiv.</em>
        </li>
        <li>
          Rives, A. et al. (2021). Biological structure and function emerge from
          scaling unsupervised learning to 250 million protein sequences.{" "}
          <em>PNAS.</em>
        </li>
      </ol>
    </div>
  );
}
